Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Aaron Kugelmass
Prof. Julinda Mehilli,
Presenter | see Discussant report
Julinda Mehili (Germany)
List of Authors: J. Mehilli, A. Kastrati, R.A. Byrne, S. Kufner, S. Massberg, K.A. Birkmeier, K-L. Laugwitz, S. Schulz, J. Pache, M. Fusaro, M. Seyfarth, A. Schömig Abstract:
Discussant | see Presenter abstract
Aaron Kugelmass (United States of America)
Dr.Mehilli and colleagues are to be congratulated on the ISAR-TEST-4 trial. The study of over 2600 patients is the largest randomized trial of a biodegradable polymer based DES to date. The study population is comparatively “non-idealized”, and reflects real world practice with both stable angina and acute coronary syndrome patients. The population mirrors that of contemporary practice both clinically, (patients with diabetes, prior infarction and/or multivessel disease), and angiographically, (mean vessel size of 2.8 mm and greater than 70% B2 or C lesions). Current DES, which have durably reduced clinical and angiographic restenosis, utilize permanent polymers. It is thought that these polymers contribute to hypersensitivity reactions, ongoing inflammation, and thrombogenicity. Thus, current polymers likely contribute to delayed angiographic and clinical events such as late lumen creep, and delayed restenosis and stent thrombosis. Thus, the appeal of DES utilizing a biodegradable polymer.
At both 30 days and twelve months, the biodegradable polymer stent was significantly non-inferior to available limus stents for both safety (cardiac death/MI) and clinical restenosis (TLR). Each of the contributing endpoints appeared similar. This is encouraging, but begets the question as to what is the appropriate clinical and angiographic surveillance period for biodegradable polymer stents. As is evident from DES, attempts to reduce vascular inflammation can result in temporal shifts in angiographic and clinical sequellae. Will the results of biodegradable polymer stents prove as durable as current DES? Hopefully ISAR-TEST-4 includes longer term clinical and angiographic follow up. With additional follow up, this data can help drive this promising technology.
Randomized trial of 3-limus agent-eluting stents with biodegradable or permanent polymer coating. ISAR-TEST-4 study
This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.
© 2017 European Society of Cardiology. All rights reserved